[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617377":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":62,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Center for Health Sciences, Serbia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental 1","EXPERIMENTAL","2,000 IU of active ingredient (powder) per day",[13],"Dietary Supplement: Experimental 1 (powdered supplement)",{"label":15,"type":16,"description":17,"interventionNames":18},"Experimental 2","ACTIVE_COMPARATOR","2,000 IU of active ingredient (oil) per day",[19],"Dietary Supplement: Experimental 2 (oily supplement)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Experimental 1 (powdered supplement)","Active powdered ingredient (2,000 IU\u002Fd)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Experimental 2 (oily supplement)","Active oily ingredient (2,000 IU\u002Fd)",[15],[32],{"name":33,"affiliation":34,"role":35},"Sergej Ostojic, MD, PhD","University of California, Los Angeles","STUDY_CHAIR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+381112643242","sergej.ostojic@chess.edu.rs",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Center for Health Sciences","RECRUITING","Belgrade","11000","Serbia","RS",{"type":50,"coordinates":51},"Point",[52,53],20.46513,44.80401,{"lat":53,"lon":52},[56,59],{"name":57,"role":38,"phone":58,"phoneExt":26,"email":40},"Sergej M Ostojic, MD, PhD","+381-11-2643-242",{"name":60,"role":61,"phone":26,"phoneExt":26,"email":26},"Nikola Todorovic, PhD","PRINCIPAL_INVESTIGATOR",{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100617377","effects-of-different-vitamin-d3-formulations-in-vitamin-d-deficient-adults-100617377",false,"NCT07317830","Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults","The Effects of Eight Weeks of Supplementation With Two Vitamin D₃ Formulations in Adults With Subclinical and Clinical Vitamin D Deficiency: A Randomized Controlled Superiority Pilot Trial","AMORPH-D","Inclusion Criteria:\n\n* Adults aged 18 years and over\n* Serum 25(OH)D \\\u003C 75 nmol\u002FL\n* BMI 18.5 - 29.9 kg\u002Fm2\n* Free of clinically significant acute disorders and severe chronic diseases\n* No planned travel to high-UV destinations or tanning bed use during the trial\n* Willing to avoid non-study vitamin D supplements\n* Able to give written informed consent and comply with study visits\n* Submitted informed consent\n\nExclusion Criteria:\n\n* Pregnancy of breast feeding\n* Underweight or obesity\n* History of any dietary supplement use within 8 weeks before screening\n* Medications that materially alter vitamin D metabolism or calcium balance\n* Subjects with a history of medicine or alcohol abuse\n* Abnormal values for lab clinical chemistry (\\> 2 SD)\n* Unwillingness to return for follow-up analysis\n* Participation in other clinical trials within 60 days prior to screening",true,"ALL","18 Years","80 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"NA","This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.",[84],"Vitamin D Deficiency","2025-12-24",{"date":87,"type":88},"2026-01-05","ACTUAL",{"date":90,"type":78},"2025-12-15",{"date":92,"type":78},"2026-06-15",{"name":5,"class":6},1]